← All trials
NCT05681351
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 13, 2022
- Primary completion
- May 31, 2026
- Completion date
- Sep 30, 2026
- First posted
- Jan 12, 2023
- Last posted
- Dec 26, 2023
- Enrollment
- 700
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ionis Pharmaceuticals, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.